Japan's Ruling Party Considers New Drug Administrative Body
This article was originally published in PharmAsia News
Facing the aftermath of the hepatitis C scandal, Japan's ruling Liberal Democratic Party organized a discussion panel on pharmaceutical policy, and the panel has proposed to establish a new administrative entity to oversee drug approval and adverse effects prevention. Currently, the Ministry of Health, Labor and Welfare, and the Pharmaceuticals and Medical Device Agency are in charge of drug review, approval and safety measures. The LDP panel is proposing to establish an independent drug administrative agency that is separate from MHLW, functioning like a Japanese version of U.S. FDA. (Click here for more - Japanese language
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.